Granules India reported a drop in third-quarter profit on Friday, hurt by pricing pressure in its key European market.

Granules India Ltd., a vertically integrated pharmaceutical company, on Friday reported a 6 percent down in its net profit to INR 1,176 Million for the quarter ended December 31, 2024, as compared to ...

Granules India’s net profit declined 6 per cent at ₹117 crore in the third quarter ended December 2024 compared to ₹125 crore ...

Granules India's net profit declines 6% due to FDA inspection, lower demand; revenue from North America rises to 77%.

Shares of Granules India Ltd. fell sharply on Friday after the pharmaceutical company reported a decline in its revenue and ...

Granules India slipped 2.85% to Rs 583.15 after its consolidated net profit fell 6.41% to Rs 117.60 crore on 1.55% decline in total revenue from operations to Rs 1,137.70 crore in Q3 FY25 over Q3 FY24 ...

Granules India net profit down 6 percent to INR 1 #176 Mn in Q3 FY25 176 mn in q3 fy25- Latest Hindi News headlines on 176 mn in q3 fy25. Stay updated with recent developments & news stories about 176 ...

The company, known for its calcium supplement Shelcal 500, reported a near 14% rise in consolidated net profit to Rs 503 ...

Granules India shares declined beyond 3.5 percent on Friday, January 24, following the announcement of its weak Q3FY25 ...

Around 20 million Americans reportedly trust this medication—here are the recall details, and the unusual error that caused ...

Granules India's revenue decreased by 1.6% year-on-year for the three months ended Dec. 31, 2024, reaching Rs 1,138 crore.

Who are peers of Granules India Ltd? The peers of Granules India Ltd are Sun Pharmaceuticals Industries Ltd, Divis Laboratories Ltd, Cipla Ltd, Dr Reddys Laboratories Ltd, Torrent Pharmaceuticals ...